-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent presents Phase 3 mazdutide obesity, diabetes trial results at ADA 2026

PUBT·05/13/2026 00:00:28
Listen to the news
Innovent presents Phase 3 mazdutide obesity, diabetes trial results at ADA 2026
  • Innovent Biologics flagged new clinical and preclinical readouts for obesity candidate mazdutide, set for presentation at 2026 American Diabetes Association Scientific Sessions in New Orleans on June 5-8.
  • Future presentations include late-stage results comparing mazdutide with semaglutide in Chinese adults with type 2 diabetes and obesity, plus Phase 3 data in adults with obesity, positioning the drug on weight loss, glucose control, and broader metabolic benefits.
  • Additional data due at the meeting include early-stage safety and pharmacokinetic findings in adolescents with obesity, extending the program into younger patients.
  • Pipeline disclosures scheduled for posters include early clinical results for daily oral GLP-1 small molecule IBI3032, preclinical efficacy for amylin analog IBI3040, and preclinical durability signals for INHBE-targeting siRNA IBI3046, underscoring a push toward oral dosing, tolerability, and longer-lasting weight control.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605122000PR_NEWS_USPR_____CN57404) on May 13, 2026, and is solely responsible for the information contained therein.